Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
复制标题
DOI：
10.1038/sj.leu.2404015
复制
发表时间：
2006-01-01
期刊：
影响因子：
11.4
通讯作者：
Nomdedéu, JF
中科院分区：
文献类型：
--
作者：
Perea, G;Lasa, A;Nomdedéu, JF
大多数患有急性髓性白血病（AML）和t（8;21）或inv（16）的患者使用当前基于蒽环类抗生素和阿糖胞苷的方案预后良好。采用流式细胞术（FC）和实时RT-PCR（RQ-PCR）对55例患者进行串联分析，其中28例携带t（8; 21），27例携带inv（16），包括1例携带新型CBFbeta/MYH 11转录物的病例。共有31%（n = 17）的CR患者复发：7例为t（8; 21），10例为inv（16）。FC检测到的复发和非复发患者的微小残留病（MRD）的平均数量有显著差异：治疗结束时为0.3% vs 0.08%（P = 0.002）。复发和非复发患者的融合转录本拷贝数/ABLx 10（4）的平均值也不同：诱导后为2385 vs 122（P = 0.001），强化后为56 vs 7.6（P = 0.0001），化疗结束时为75 vs 3.3（P = 0.0001）。治疗结束时FC MRD水平为40.1%的患者的复发率高于
Most patients with acute myeloid leukemia (AML) and t(8;21) or inv(16) have a good prognosis with current anthracycline- and cytarabine-based protocols. Tandem analysis with flow cytometry (FC) and real-time RT-PCR (RQ-PCR) was applied to 55 patients, 28 harboring a t( 8; 21) and 27 an inv( 16), including one case with a novel CBFbeta/MYH11 transcript. A total of 31% (n = 17) of CR patients relapsed: seven with t( 8; 21) and 10 with inv( 16). The mean amount of minimal residual disease (MRD) detected by FC in relapsed and nonrelapsed patients was markedly different: 0.3 vs 0.08% ( P = 0.002) at the end of treatment. The mean number of fusion transcript copies/ ABLx10(4) also differed between relapsed and non-relapsed patients: 2385 vs 122 ( P = 0.001) after induction, 56 vs 7.6 after intensification ( P = 0.0001) and 75 vs 3.3 ( P = 0.0001) at the end of chemotherapy. Relapses were more common in patients with FC MRD level 40.1% at the end of treatment than in patients with